Neoplasm Clinical Trial
Official title:
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Brain metastases are the most common adult intracranial tumor, occurring in approximately
10% to 30% of adult cancer patients, and represent an important cause of morbidity and
mortality in this population. The standard of care for solitary brain metastasis is surgery
followed by whole brain radiation therapy (WBRT). Without WBRT, there are unacceptably high
levels of local failure that occur. Local recurrence rates ranged from approximately 45% at
1 year to 60% at 2 years after resection alone. However, aside from improvements in
intra-cranial control, it is well documented that WBRT is associated with serious long term
side effects, including significant decline in short term recall by as early as 4 months
after treatment.
Many centers are now offering patients stereotactic radiosurgery (SRS) to the cavity after
resection alone to improve local control while avoiding the negative effects of WBRT. There
have been several retrospective studies on the use of SRS to the resection cavity alone,
from which the 1 year actuarial local control rates range from 35% - 82%. The high rate of
in-field local failure suggests that the current dosing regimen used may not be high enough
for adequate local control. Currently, the highest local control rates are approximately
80%, but there may be room for improvement with increased dose without significantly
increasing the risk of side effects.
The investigators propose a trial for patients after surgical resection of solitary brain
metastases. The purpose of this trial will be to determine the maximum tolerated dose for
single fraction SRS to the resection cavity. There will be three groups based on the
resection cavity size. Dose escalation enrollment will be done sequentially within each
cohort. You will know which cohort and which specific dose level you are randomized to.
After treatment, which will take one day, regardless of cohort, you will be followed closely
for treatment outcome and possible side effects. You will be asked to complete three quick
surveys at each follow-up appointment regarding quality of life and memory in addition to
standard of care surveillance brain MRI and physical exam.
Brain metastases are the most common adult intracranial tumor, occurring in approximately
10% to 30% of adult cancer patients, and represent an important cause of morbidity and
mortality in this population. The risk of developing brain metastases differs with different
primary tumor histologies, with lung cancer accounting for approximately one half of all
brain metastases. The prognosis of patients with brain metastases is poor. The median
survival time of untreated patients is approximately 1 month. With treatment, the overall
median survival time after diagnosis is approximately 4 months. The Radiation Therapy
Oncology Group (RTOG) recursive partitioning analysis (RPA) describes three prognostic
classes, defined by age, Karnofsky Performance Score (KPS), and disease status. The most
widely used treatment for patients with multiple brain metastases is whole brain radiation
therapy (WBRT). The appropriate use of WBRT can provide rapid attenuation of many
neurological symptoms, improve quality of life, extend median survival, and be especially
beneficial in patients whose brain metastases are surgically inaccessible or when other
medical considerations preclude surgery. The use of adjuvant WBRT after resection or
stereotactic radiosurgery (SRS) has been proven to be effective in terms of improving local
control of brain metastases, and thus, the likelihood of neurological death is decreased.
The standard of care for solitary brain metastasis is surgery followed by WBRT. In a study
by Patchell et al. for solitary brain metastases status post resection, the addition of
whole brain radiation significantly reduced local recurrence from approximately 45% to 10%
after resection. Although it does not prolong survival or functional independence, this
treatment regimen was shown to result in significantly improved loco-regional control. A
more recent study from the European Organization for Research and Treatment of Cancer
(EORTC) randomized patients who underwent gross total resection (GTR) of up to 3 brain
metastases to adjuvant WBRT versus observation. Adjuvant WBRT resulted in significantly
reduced intracranial failure and neurologic death, however again both overall survival and
functionally independent survival were not different. Among the major findings of both of
these studies are the unacceptably high levels of local failure that occur after GTR alone.
Local recurrence rates ranged from approximately 45% at 1 year to 60% at 2 years after
resection.
However, aside from improvements in intra-cranial control, it is well documented that WBRT
is associated with serious long term side effects, including significant neurocognitive
decline. A randomized study conducted by Chang et al of SRS versus SRS + WBRT for 1 - 3
brain metastases found that addition of WBRT was associated with significantly worse memory
recall as early as 4 months. A conclusion of this study was that a regimen of close
surveillance and SRS as necessary is preferred over SRS + WBRT because the neurocognitive
effects of WBRT may actually be worse than that caused by intracranial disease recurrence.
Many centers are now offering patients SRS to the cavity after resection alone to improve
local control while avoiding the negative effects of WBRT. There have been several
retrospective studies on the use of SRS to the resection cavity alone, from which the 1 year
actuarial local control rates range from 35% - 82%. The radiation necrosis rates from these
same studies range from 2% - 6%. In currently unpublished data from Emory University
reviewing 63 patients with 65 cavities treated between 01/2007 and 08/2010, the 1 year
actuarial local control rate was 78%. Of the 10 local failures, 70% were in-field only, 10%
were marginal only, and 20% were both. The high rate of in-field failure suggests that the
current dosing regimen used may be insufficient for optimal local control. The current SRS
dose constraints used are derived from the phase I trial RTOG 90-05. This study determined
the maximum tolerated dose for SRS in previously irradiated patients with unresected brain
metastases based on lesion size. The maximum doses currently used may be artificially low
for resected patients for several reasons. First, the patient population studied had been
previously irradiated which most likely lowered the maximum tolerated dose versus a
non-irradiated population. Secondly, the typical planning target volume (PTV) of the
resection bed is the cavity with a 1 - 2mm margin. This means that the vast majority of the
irradiated PTV is not brain parenchyma, but actually cerebrospinal fluid (CSF), which should
result in a lower radiation necrosis rate for the same dose/volume. Currently, the highest
local control rates are approximately 80%, but there may be room for improvement with
increased dose without significantly increasing the risk of radiation necrosis.
The investigators propose a prospective phase I trial for patients status post surgical
resection of solitary brain metastases. The purpose of this trial will be to determine the
maximum tolerated dose for single fraction SRS to the resection cavity. The investigators
believe that the current SRS dosing constraints may be too low, and that a larger
therapeutic window exists for this patient population. Results from this trial may form the
basis of future trials directly comparing WBRT with SRS to the cavity alone following
resection of solitary brain metastases. This phase III study would answer the question about
as to whether local irradiation is adequate treatment for patients following surgery for
metastatic brain disease. Also it is anticipated that QOL measures would be built into the
study in an attempt to confirm the data reported by Chang that WBRT is associated with a
significant decline in QOL at even early endpoints.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00199836 -
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
|
Phase 1 | |
Completed |
NCT01672944 -
Evaluating Biobanking Educational Tools
|
N/A | |
Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
Completed |
NCT02747342 -
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
|
Phase 1 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02536586 -
A Study of LY3023414 in Japanese Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
Completed |
NCT02394821 -
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
|
Phase 3 | |
Completed |
NCT01457196 -
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
|
N/A | |
Completed |
NCT00143533 -
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05450562 -
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT00001341 -
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
|
Phase 1 | |
Completed |
NCT01425008 -
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05101798 -
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
|
Phase 2 | |
Completed |
NCT01920061 -
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
|
Phase 1 | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|